Cash Flow Statement (Annual)
BGB / Blackstone / GSO Strategic Credit Fund Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities Continuing Operations|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Net Realized Gains Losses On Investments Funds Related||135,243||-337,932||-540,353||-710,755||-1,792,106||-3,343,635||-4,121,003||-2,023,503||-4,613,531|
|Unrealized Gain Loss On Investments||-||-||-||-||-||-||-722,064||241,617||21,589|
|Non Cash Performance Allocations||-||-||-||-||-||-||-||-||-|
|Non Cash Performance Allocations And Incentive Fee Compensation||-||-||-||-||-||-||-||-||-|
|Share Based Compensation||3,048,108||2,440,148||1,396,062||949,633||855,087||734,733||629,642||323,651||338,687|
|Amortization Of Intangible Assets||158,048||162,051||207,591||139,174||95,671||101,915||101,437||82,943||46,776|
|Other Noncash Income Expense||-25,243||-20,591||-164,359||-353,052||-206,451||-121,808||-144,657||-16,711||-362,865|
|Increase Decrease In Operating Capital|
|Increase Decrease In Cash Acquired With Consolidation Of Fund Entity||-||-||-||-||-||-||-||-||-|
|Increase Decrease In Cash Of Discontinued Operations||-||-4,398||-110,607||-48,284||-173,726||-476,533||-442,370||-||-33,566|
|Increase Decrease In Accounts Receivable||-35,050||108,162||-116,714||60,520||46,580||-229,331||213,706||-87,074||-282,026|
|Increase Decrease In Receivables Under Repurchase Agreements||-||-||-||-||-99,034||-148,984||204,893||-86,398||-118,495|
|Increase Decrease Due From Affiliates||-467,449||68,761||31,403||73,485||-237,169||-229,837||97,487||57,907||298,501|
|Increase Decrease In Other Operating Assets||-82,386||20,802||19,233||-51,031||-15,445||82,890||149,732||-99,108||-17,377|
|Increase Decrease In Accrued Salaries||-94,931||-101,377||-273,281||-119,862||-454,724||-836,852||-917,428||-572,814||-1,177,852|
|Increase Decrease In Financial Instruments Sold Not Yet Purchased||-||-||-||-||-||-||96,780||42,761||-62,730|
|Increase Decrease In Accounts Payable And Accrued Liabilities||-987,241||12,535||-203,419||-408,256||-316,082||-305,978||-474,652||-214,651||-755,165|
|Increase Decrease In Payables Under Repurchase Agreements||-||-||-||-||-||-||11,012||34,286||43,516|
|Increase Decrease In Due To Affiliates||-261,685||3,286||-3,439||-88,425||-216,671||35,504||-102,847||39,035||-9,652|
|Decrease In Financial Instruments Used In Operating Activities||-||-||-||-||-||10,979,850||7,937,114||8,798,358||19,573,150|
|Increase In Financial Instruments Used In Operating Activities||-||-||-||-||-||13,648,180||10,621,190||8,195,594||18,723,360|
|Net Cash Provided By Used In Operating Activities Continuing Operations||-||-||-||583,155||3,547,941||1,654,989||2,397,043||-541,286||-2,448,740|
|Net Cash Provided By Used In Investing Activities Continuing Operations|
|Payments To Acquire Property Plant And Equipment||23,627||54,160||36,484||37,020||25,637||30,271||59,247||21,826||24,347|
|Net Cash Provided By Used In Investing Activities Continuing Operations||-||-||-||-222,981||-165,904||-24,425||-53,404||-28,976||-188,208|
|Net Cash Provided By Used In Financing Activities Continuing Operations|
|Payments Of Dividends Minority Interest||92,531||113,872||608,287||261,582||844,011||982,405||677,110||533,925||813,987|
|Proceeds From Minority Shareholders||205,558||262,006||1,183,952||773,714||1,114,457||1,560,183||479,678||329,005||759,907|
|Payments Of Tax Receivable Agreement||-||-||-||-||-||86,733||84,484||78,985||135,831|
|Net Settlement Of Vested Common Units And Repurchase Of Common And Partnership Units||-||-||-||-||-||-||-||-||-|
|Proceeds From Loans||593,989||415,828||13,301||633,742||11,367||491,150||2,423,614||3,321,081||7,600,153|
|Repayments Of Long Term Debt||323,993||43,266||27,424||33,168||16,777||8,735||517,629||420,714||1,766,129|
|Payments Of Capital Distribution||-||599,390||702,832||614,530||1,469,479||2,348,596||3,497,346||2,018,669||2,842,582|
|Net Cash Provided By Used In Financing Activities Continuing Operations||-||-||-||-405,411||-3,259,614||-1,049,907||-1,919,402||570,170||2,771,339|
|Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect||-||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-||-|
|Supplemental Cash Flow Information|
|Income Taxes Paid||52,035||57,672||43,945||30,234||69,858||236,718||115,814||65,790||106,032|
|Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed|
|Non Cash Contributions From Non Controlling Interest Holders||-||-||-||6,803||63,273||47,683||2,277||1,155||1,112|
|Non Cash Distributions To Non Controlling Interest Holders||-||-||-||-6,803||18,537||60,589||-34||-13,536||-69,721|
|Transfer Of Interests To Non Controlling Interest Holders||1,991||-21,996||2,614||-4,584||-2,403||-1,885||-12,272||-8,278||-6,016|
|Change Of Parent Ownership Interest||-||-19,346||-5,893||-2,423||-2,519||9,032||92,785||7,881||-15,197|
|Net Settlement Of Vested Common Units||199,447||198,739||186,644||167,046||153,522||69,426||139,941||101,898||127,392|
|Conversion Of Stock Amount Issued1||-109,748||252,113||-228,722||256,239||43,255||117,877||131,883||77,520||59,334|
|Deferred Tax Asset Exchange Of Founders And Senior Managing Directors Interests In Partnership Holdings||-142,982||351,183||-300,471||204,320||113,757||105,686||195,291||59,304||74,487|
|Due To Affiliates From Non Cash Financing Activities Exchange Of Related Parties||-||-||-||-||33,177||82,704||130,264||53,935||63,430|
|Partners Capital Account Period Increase Decrease Exchange Of Related Parties||-||-||-||-||80,580||22,982||65,027||5,369||11,057|
|Issuance Of Common Partners Units||-||-||-||-||-||-||-||-||-|
Peers - Investment Advice (6282)
AMP / Ameriprise Financial, Inc.
APO / Apollo Global Management LLC
ARES / Ares Management, L.P.
BGX / Blackstone / GSO Long-Short Credit Income Fund
BSIG / BrightSphere Investment Group plc
BX / Blackstone Group L.P. (The)
CNS / Cohen & Steers Inc.
EVR / Evercore Partners, Inc.
FIG / Fortress Investment Group LLC
11h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET